OTCMKTS:CRXTQ Clarus Therapeutics (CRXTQ) Stock Price, News & Analysis $0.0010 0.00 (0.00%) (As of 03/6/2023) Add Compare Share Share Today's Range$0.0010▼$0.001050-Day Range N/A52-Week Range$0.00▼$3.94VolumeN/AAverage Volume73,151 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Clarus Therapeutics alerts: Email Address Ad Porter & CompanyTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. Hopelessness abounds. And looking in, the future here looks bleak for these forgotten souls. But in a strange twist of fate, something miraculous is taking place…Go here now to watch my new documentary About Clarus Therapeutics Stock (OTCMKTS:CRXTQ)Clarus Therapeutics Holdings, Inc., a pharmaceutical company, focuses on the development and commercialization of oral testosterone replacement therapy in the United States. It offers JATENZO, a soft gel oral formulation of testosterone undecanoate for treating hypogonadal men. The company has a licensing agreement with HavaH Therapeutics for product to treat androgen therapies for inflammatory breast disease and certain forms of breast cancer; and license agreement with The Royal Institution for the Advancement of Learning/McGill University to develop and commercialize McGill's proprietary technology designed to treat conditions associated with CoQ10 deficiencies in humans. Clarus Therapeutics Holdings, Inc. was founded in 2003 and is based in Northbrook, Illinois.Read More CRXTQ Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CRXTQ Stock News HeadlinesJanuary 5, 2024 | benzinga.comClarus Stock (NASDAQ:CLAR), Analyst Ratings, Price Targets, PredictionsOctober 12, 2022 | benzinga.comClarus Therapeutics Hldgs Stock (OTC:CRXWQ), Earnings Estimates, EPS, and RevenueSeptember 8, 2024 | Paradigm Press (Ad)Kamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppet masters are planning this dirty election move… October 12, 2022 | benzinga.comClarus Therapeutics Hldgs Stock (OTC:CRXWQ), Analyst Ratings, Price Targets, PredictionsSeptember 5, 2022 | finance.yahoo.comClarus Therapeutics Holdings, Inc. Announces Plan for Near-Term Sale of JATENZO® Using Structured Process Through Chapter 11 of the U.S. Bankruptcy CodeJuly 28, 2022 | finance.yahoo.comClarus Therapeutics Announces Notice of Allowance for Additional Patent Claims Covering JATENZO® (testosterone undecanoate)July 20, 2022 | wsj.comClarus Therapeutics Holdings Inc.July 12, 2022 | finance.yahoo.comClarus Therapeutics Holdings, Inc. (CRXT)September 8, 2024 | Paradigm Press (Ad)Kamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppet masters are planning this dirty election move… June 9, 2022 | finance.yahoo.comClarus Therapeutics to Present New Data for JATENZO® (testosterone undecanoate) at ENDO 2022, the Endocrine Society’s Annual MeetingMay 18, 2022 | seekingalpha.comClarus' oral testosterone product Jatenzo gets patent nodMay 18, 2022 | finance.yahoo.comClarus Therapeutics Announces Issuance of Patent Covering JATENZO® (testosterone undecanoate)May 16, 2022 | seekingalpha.comClarus Therapeutics Holdings, Inc. (CRXT) CEO Bob Dudley on Q1 2022 Results - Earnings Call TranscriptMay 16, 2022 | investing.comClarus Therapeutics Misses Q1 EPS by 21cMay 16, 2022 | finance.yahoo.comClarus Therapeutics Reports First Quarter 2022 Financial and Operating ResultsMay 13, 2022 | seekingalpha.comClarus Therapeutics Q1 2022 Earnings PreviewMay 12, 2022 | finance.yahoo.comClarus Therapeutics to Report First Quarter 2022 Financial and Operating ResultsMay 10, 2022 | finance.yahoo.comClarus Therapeutics Announces Notice of Allowance for Patent Claims Covering CLAR-121 (Testosterone + Anastrozole) for Treatment of Androgen-Mediated Autoimmune Inflammatory MastitisSee More Headlines Receive CRXTQ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Clarus Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/18/2021Today9/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolOTCMKTS:CRXTQ CUSIPN/A CIK1817944 Webwww.clarustherapeutics.com Phone847-562-4300FaxN/AEmployees2Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$13.96 million Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesDr. Robert E. Dudley Ph.D. (Age 67)Founder, Pres, CEO & Director Comp: $800.67kMr. Richard Dale Peterson (Age 54)Chief Financial Officer Comp: $583.99kMr. Frank A. Jaeger M.A. (Age 51)M.B.A., Chief Commercial Officer Comp: $510.3kMr. Steve StarkVP of Commercial Analytics & OperationsMr. Steven A. Bourne CPA (Age 60)Chief Admin. Officer, Sec. & Treasurer Ms. Kara J. StancellVP of Investor Relations & Corp. CommunicationsMs. Rozita PassarellaVP of MarketingMr. Mike ClevelandVP of SalesDr. Jay Newmark M.B.A.M.D., Chief Medical OfficerMr. James HollowaySr. VP of Manufacturing & SupplyMore ExecutivesKey CompetitorsAdvanced Life SciencesOTCMKTS:ADLSAVAX TechnologiesOTCMKTS:AVXTMymeticsOTCMKTS:MYMXNeurobiological TechnologiesOTCMKTS:NTIIOmni Bio PharmaceuticalOTCMKTS:OMBPView All Competitors CRXTQ Stock Analysis - Frequently Asked Questions How have CRXTQ shares performed this year? Clarus Therapeutics' stock was trading at $0.0010 on January 1st, 2024. Since then, CRXTQ shares have increased by 0.0% and is now trading at $0.0010. View the best growth stocks for 2024 here. How were Clarus Therapeutics' earnings last quarter? Clarus Therapeutics Holdings, Inc. (OTCMKTS:CRXTQ) released its quarterly earnings data on Thursday, November, 18th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.81) by $0.55. The company earned $4.29 million during the quarter, compared to analysts' expectations of $3.30 million. How do I buy shares of Clarus Therapeutics? Shares of CRXTQ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:CRXTQ) was last updated on 9/8/2024 by MarketBeat.com Staff From Our PartnersLast Call for Crypto Summit (RSVP FREE)The Dow recently shed nearly 1,000 points in a single day… Big tech stocks are getting slaughtered… And ...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredExposed: 3 CENT Crypto to Explode September 23rd?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Clarus Therapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Clarus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CRXTQ Stock Alerts